Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13361937 | 1.00 | CCR2 (0.84) | CCR2CCR5 | |
| SCHEMBL3326342 | 1.00 | CCR2 (0.84) | CCR2CCR5 | |
| SCHEMBL3326295 | 0.92 | CCR2 (1.00) | CCR2CCR5 | |
| SCHEMBL13361938 | 0.92 | CCR2 (1.00) | CCR2CCR5 | |
| SCHEMBL3327106 | 0.90 | CCR2 (1.00) | CCR2CCR5 | |
| SCHEMBL3360369 | 0.90 | CCR2 (1.00) | CCR2CCR5 | |
| SCHEMBL13361832 | 0.90 | CCR2 (1.00) | CCR2CCR5 | |
| SCHEMBL3326201 | 0.84 | CCR2 (0.70) | CCR2CCR5 | |
| SCHEMBL18901611 | 0.84 | CCR2 (0.70) | CCR2CCR5 | |
| SCHEMBL13361939 | 0.84 | CCR2 (0.70) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | claimed |
| US-8470827-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-06-25 | — | — | US | claimed |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2010-05-13 | — | — | US | claimed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8470827-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885 |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.